Pfizer (PFE) expects to return to consistent growth by 2029, targeting high-single-digit annual revenue increases through 2033, supported by a predictable post-patent portfolio transition and a pipeline of new drugs, including potential weight-loss treatments, to offset declining Covid-related revenues, The Wall Street Journal’s Peter Loftus reports, citing comments made by CEO Albert Bourla.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- Midday Fly By: Palantir reports ‘beat and raise,’ Coinbase to cut staff
- BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports
- Trump Trade: Microsoft, Google agree to U.S. security reviews of AI models
- These Are the Stocks Reporting Earnings Today – May 5, 2026